The Risks as stated by NWBO is a.) confounding of the nOS data and b.) the manipulated protocol, comparator, endpoints and SAP that have not been approved by regulators. That's was NWBO states in their SEC filing. So basically everything about the trial -- validity of the data, and the manipulated trial protocol and rGBM endpoint.
Market Data 
Markets 
AI
